705 related articles for article (PubMed ID: 20226957)
1. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
Funder JW
Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
[TBL] [Abstract][Full Text] [Related]
2. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system.
Mihailidou AS; Funder JW
Steroids; 2005; 70(5-7):347-51. PubMed ID: 15862816
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
4. RALES, EPHESUS and redox.
Funder JW
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
[TBL] [Abstract][Full Text] [Related]
5. Reconsidering the roles of the mineralocorticoid receptor.
Funder JW
Hypertension; 2009 Feb; 53(2):286-90. PubMed ID: 19139379
[No Abstract] [Full Text] [Related]
6. Aldosterone receptor antagonists.
Azizi M
Ann Endocrinol (Paris); 2021 Jun; 82(3-4):179-181. PubMed ID: 32473789
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Young MJ; Funder JW
J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
[TBL] [Abstract][Full Text] [Related]
8. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Funder JW
Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone as a cardiovascular risk factor.
Rossi G; Boscaro M; Ronconi V; Funder JW
Trends Endocrinol Metab; 2005 Apr; 16(3):104-7. PubMed ID: 15808807
[TBL] [Abstract][Full Text] [Related]
10. Why are mineralocorticoid receptor antagonists cardioprotective?
Chai W; Danser AH
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
[TBL] [Abstract][Full Text] [Related]
11. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
12. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone, organ damage and dietary salt.
Catena C; Colussi G; Sechi LA
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Colussi G; Catena C; Sechi LA
J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone, mineralocorticoid receptor, and heart failure.
Messaoudi S; Azibani F; Delcayre C; Jaisser F
Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone, mineralocorticoid receptors and vascular inflammation.
Funder JW
Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Galuppo P; Bauersachs J
Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
[TBL] [Abstract][Full Text] [Related]
18. Extrarenal effects of aldosterone.
Nguyen Dinh Cat A; Jaisser F
Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):147-56. PubMed ID: 22240440
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone receptor antagonists: current perspectives and therapies.
Guichard JL; Clark D; Calhoun DA; Ahmed MI
Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Whaley-Connell A; Johnson MS; Sowers JR
Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
